erosion chronic myeloid leukaemia stem cell pool ppar gamma agonists 
whether cancer maintained small number stem cells composed proliferating cells approximate phenotypic equivalency central question cancer biology1 stem cell hypothesis relapse treatment may occur failure eradicate cancer stem cells chronic myeloid leukaemia cml quintessential hypothesis cml myeloproliferative disorder results dysregulated tyrosine kinase activity fusion oncoprotein bcr-abl2 chronic phase sole genetic abnormality chromosomal translocation ph+: t9;22q34;q11 stem cell level causes increased proliferation myeloid cells without loss capacity differentiate without treatment patients progress blast phase additional oncogenic mutations result fatal acute leukaemia made proliferating immature cells imatinib mesylate tyrosine kinase inhibitors tkis target kinase activity bcr-abl improved patient survival markedly however fewer % patients reach stage complete molecular response cmr defined point bcr-abl transcripts become undetectable blood cells3 failure reach cmr results inability tkis eradicate quiescent cml leukaemia stem cells lscs2- show residual cml lsc pool can gradually purged glitazones antidiabetic drugs agonists peroxisome proliferator-activated receptor-gamma ppar gamma found activation ppar gamma glitazones decreases expression stat5 downstreamtargets hif2 alpha5 cited26 key guardians quiescence stemness cml lscs pioglitazone given temporarily three cml patients chronic residual disease spite continuous treatment imatinib achieved sustained cmr years withdrawal pioglitazone suggests clinically relevant cancer eradication may become generally attainable goal combination therapy erodes cancer stem cell pool 
